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ABSTRACT
Summary: The calibrated population resistance (CPR) tool is a
web-accessible program for performing standardized genotypic
estimation of transmitted HIV-1 drug resistance. The program is
linked to the Stanford HIV drug resistance database and can
additionally perform viral genotyping and algorithmic estimation of




Antiretroviral (ARV) therapy has greatly advanced the management
of human immunodeﬁciency virus type 1 (HIV-1) infection.
When used in combination, ARV drugs targeting the viral reverse
transcriptase (RT) and protease (PR) activities can suppress HIV-1
replication to undetectable levels, leading to signiﬁcant clinical
beneﬁt. However, a number of factors can lead to the emergence
of drug-resistant virus strains. Once drug-resistant strains have
emerged, they are ‘archived’ in resting white blood cells and can
rapidly re-emerge if therapeutic regimens using drugs to which
they are resistant are restarted. Expert panels recommend that,
where possible, selection of ARV drug regimens should be guided
by ‘genotypic’ screening in which viral drug resistance mutations
(DRMs) are identiﬁed by population sequencing of the dominant
HIV-1 strain in plasma. A number of software and web resources
have been developed to support this procedure (Liu and Shafer,
2006).
Drug-resistant viruses selected by treatment can be transmitted,
potentially compromising options for ﬁrst line therapy in untreated
individuals (Kuritzkes et al., 2008). Surveillance of HIV-1 drug
resistance (HIVDR) is therefore crucial to maintain the success of
HIV-1 prevention efforts. However, variations in the methodologies
used for surveillance of transmitted HIVDR, such as the speciﬁc
DRMs taken as indicating transmitted resistance, have so far limited
the potential to draw general conclusions from these studies. There
is a widely recognized requirement for standardized protocols in
this area, so that trends in HIVDR can be investigated through
comparison between studies performed in distinct geographic
regions and over time (Pillay, 2004; van de Vijver et al., 2007).
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We recently published a list of standard surveillance DRMs
(SDRMs), endorsed by the World Health Organization (WHO) for
epidemiological surveillance of transmitted HIVDR (Bennett et al.,
2008b; Shafer et al., 2007, 2008). Here we describe an online
program, the calibrated population resistance (CPR) tool, providing
a standardized framework for estimating transmitted HIVDR from
population-sampled HIV-1 PR and RT sequence sets.
2 FUNCTIONALITY
The CPR program accepts FASTA-formatted HIV-1 PR and/or
RT sequence data. Options to carry out genotyping (subtyping)
and to estimate genotypic resistance to speciﬁc ARV drugs are
provided. A proﬁle alignment of the submitted sequence set is
created by aligning each nucleotide sequence to a polypeptide
reference sequence for the region of the HIV-1 genome encoding
PR and RT (by default, a subtype B consensus sequence, available
from http://hivdb.stanford.edu/). Mutations, deletions and insertions
(deﬁned as changes relative to the reference sequence) are recorded
foreachsubmittedsequence.Theprevalenceofindividualmutations
is calculated by dividing mutation frequency by the number of
valid codons at the corresponding position in the alignment. CPR
implements a standard approach to handling contingencies such
as missing data (i.e. incomplete sequences) and the nucleotide
ambiguities common in HIV-1 sequence data obtained through
populationsequencingofviralRNA.Theseproceduresaredescribed
in the program release notes.
A list of DRMs (by default the most recent version of the SDRM
list) is used to compute the prevalence of resistance to each of the
threemainclassesofARVdrug:proteaseinhibitors(PIs),nucleoside
RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs).
TheprevalenceoftransmittedHIVDRtoeachdrugclassisestimated
asthenumberofsequencescontaininganyDRMspeciﬁctothatdrug
class relative to the number of times the target gene is represented
in the alignment.
Analysis generates a report that summarizes the input dataset in
terms of drug resistance, genetic diversity and sequence quality.
The CPR report includes a graphical overview of DRMs and
resistance-associated mutations present in the input dataset, and a
plot showing coverage across the target region (i.e. the PR and RT
genes). If the option to perform genotypic estimation of resistance is
selected, resistance scores [ranging from 1 (susceptible) to 5 (highly
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resistant)] to speciﬁc PI, NRTI and NNRTI drugs are shown for each
sequence. Once the report is generated the submitted sequences are
deleted.
The HIV drug resistance database (HIVDB) is used to develop
a list of PR and RT amino acid variants that have been observed
at a prevalence of 0.1% in a database containing sequences from
about 20 000 individuals (Rhee et al., 2003). Atypical mutations
that have been reported less frequently and that are not known
drug-resistant variants are highlighted in the report. APOBEC3G-
mediated sequence editing [see, Holmes et al. (2007) for review]
is detected using a subset of atypical mutations that typically occur
in edited sequences (Gifford et al., 2008). Other sequence quality
indicators, such as stop codons and frameshifts are also identiﬁed
and listed in a quality analysis section of the report.
A number of mutations have been described that are marginal
with respect to their inclusion on the SDRM list, and an option
is provided to highlight these ‘borderline/suspicious’ mutations
in the report in addition to SDRMs. The CPR report shows the
prevalence of individual mutations in the query dataset alongside
their corresponding prevalence (stratiﬁed by subtype) in sequences
from untreated patients in HIVDB. This allows investigators to
rapidly identify sequence polymorphisms that are disproportionally
represented in query datasets, and to discriminate between subtype-
speciﬁc polymorphisms, sequence quality problems and mutational
markers of prior-drug selection pressure. Mutation lists used within
the program are standardized and version-tracked, as it is expected
that changes may occur as new information about drug resistance
and viral polymorphism becomes available.
The CPR tool is written in PERL and can readily be installed on
computers running UNIX or LINUX operating systems.Alignments
are constructed using LAP(Huang and Zhang, 1996).Viral subtypes
are assigned using STAR (Myers et al., 2005). Genotypic estimation
of resistance is performed using the Stanford SIERRA web service.
3 DISCUSSION
TheCPRtoolaimstopromoteconsistencybetweenepidemiological
studies by providing investigators worldwide with ready access to a
simple, standard protocol for genotypic estimation of transmitted
HIVDR. Because the CPR tool is closely linked to HIVDB, it
allows investigators to leverage the power of large quantities of
published HIV-1 sequence data within their analyses. Additionally,
by standardizing protocols for genotypic estimation of transmitted
HIVDR, the CPR program can facilitate comparison between
sequence datasets that cannot be shared due to legal or proprietary
constraints. These include datasets collated by some of the largest
national and international surveillance programs (Little et al., 2002;
SPREAD programme, 2008; UK Collaborative Group on HIV Drug
Resistance, 2007; Yerly et al., 2007).
In regions of the world with minimal health infrastructure and
large numbers of HIV-1 infected individuals, management of ART
is necessarily based on simpliﬁed, standard treatment protocols
(Bennettetal.,2008a;Gilksetal.,2006).TheWHOhasdevelopeda
minimum-resource approach for surveillance of transmitted HIVDR
to accompany the expansion of access to ART in these regions,
based on routine genotypic screening in a representative subset
of the HIV-infected, untreated population (Bennett et al., 2008b).
Due to resource constraints, the number of individuals surveyed
is likely to be small (47), and surveillance is likely to rely
partly on archived and convenience samples (Bertagnolio et al.,
2007). Since the threshold for implementing changes inART policy
is low [>5% prevalence of transmitted HIVDR (Bennett et al.,
2008b)] it is crucial that protocols deal accurately and consistently
with the contingencies of sequence analysis. The quality control
measures implemented in CPR will help investigators to identify
artifacts in sequence datasets collected for surveillance purposes
[e.g. spurious ‘drug resistance mutations’ introduced by APOBEC-
mediated sequence editing (Gifford et al., 2008)] so that expensive
and unnecessary changes in health policy may be avoided.
Although designed speciﬁcally for surveillance of HIVDR, we
propose that the framework implemented in the CPR program
represents a prototype for other areas of molecular epidemiology—
in particular studies of microbial drug resistance—in which the
primary unit of analysis is a population-sampled set of sequences.
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